Carta Healthcare, whose software platform applies artificial intelligence to structured and unstructured data to reduce data extraction time and costs, acquired Realyze Intelligence, which applies similar technology to oncology.
Founded in 2019, San Francisco-based Carta Healthcare said it applies artificial intelligence and expert clinical data extractors to serve a wide range of health systems across the country, from independent community hospitals to large academic medical centers. It includes Mass General Brigham, CommonSpirit and Grady among its health system clients.
Realyze Intelligence was formed in 2020 as a portfolio company of UPMC Enterprises, the innovation, commercialization and venture capital arm of UPMC. Its software analyzes structured and unstructured data in electronic medical records to identify ideal patients for clinical trials and other research studies. The company claims that its doctor-trained AI can assemble appropriate cohorts in seconds instead of the typical hours or days the process consumes when done manually. Realyze Intelligence is used by cancer centers and is part of the Innovation Center at Memorial Sloan Kettering Cancer Center. The CancerX Accelerator Program also selected Realyze Intelligence as part of its inaugural program earlier this year.
Terms of the acquisition were not disclosed.
An analysis by Realyze Intelligence found that using the software, UPMC Hillman Cancer Center saw seven times as many patients matched to trials and twice as many enrolled, compared to the same period without using the software.
“We believe data is the most important ingredient to improving healthcare,” Brent Dover, CEO of Carta Healthcare, said in a statement. “From clinical trials to clinical registries, physicians are faced with insurmountable amounts of data packed with valuable information to improve care practices and patient outcomes. “We are inspired by Realyze Intelligence’s shared ability to use physician-trained AI and a human approach to maximize insights from clinical data, for clinical trials and cancer registries.”
“Health systems and pharmaceutical companies invest billions annually to identify and enroll patients in clinical trials, a process that is not only expensive but labor-intensive and time-consuming,” said Aaron Brauser, founder and CEO of Realyze Intelligence. , in a statement. “Timely, high-quality data is essential to accurately identify eligible patients, but many of them remain trapped in EHRs and other systems. “We are excited to revolutionize clinical trial comparison and repurpose data to improve research, optimize care pathways and improve patient outcomes with Carta Healthcare.”
